Skip to main content
. Author manuscript; available in PMC: 2021 May 1.
Published in final edited form as: Expert Opin Drug Discov. 2020 Dec 1;16(5):497–511. doi: 10.1080/17460441.2021.1851188

Figure 5.

Figure 5.

(A) Chemical structure and in vivo metabolic pathway of auranofin. Auranofin is a pro-drug, which is metabolized leading to tetraacetylthioglucose and to the bioactive fragment [Au(PEt3)]+ (AUF). (B) X-ray structure of the NCP displaying the binding of Auranofin (AUF) and RAPTA-T at distal histone sites, separated by ~35 Å.